BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...
Hosted on MSN18h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is ...
The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for beef tallow products that were illegally imported from Mexico and are ...
Lockheed Martin has felt financial strain as early funding for the upcoming F-35 jets dried up, but kept working on them to avoid supply chain disruptions.
Netflix announced in April 2024 that it had officially ordered and put into production a new action thriller called Ad Vitam, which translates to To Life in English. The movie has since completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback